1	Discrepancies between feline coronavirus antibody and nucleic acid detection in			
2	effusions of cats with suspected feline infectious peritonitis			
3				
4	Eleonora Lorusso,ª Viviana Mari,ª Michele Losurdo,ª Gianvito Lanave,ª Adriana Trotta,ª Giulia			
5	Dowgier,ª Maria Loredana Colaianni, ^b Andrea Zatelli, ^c Gabriella Elia,ª Domenico Buonavogliaª			
6	Nicola Decaro ^{a,*}			
7				
8	^a Department of Veterinary Medicine, University of Bari, Strada per Casamassima Km 3,			
9	70010 Valenzano (Bari), Italy.			
10	^b Istituto Zooprofilattico Sperimentale di Puglia e Basilicata, via Manfredonia 20, 71121			
11	Foggia, Italy.			
12	^c Pharmacross Co Ltd, 60, Suite 6, G Cali Street, Ta' Xbiex XBX 1424 - Malta			
13 14 15 16 17 18	Running title: FCoV antibodies and RNA in effusions from FIP-suspected cats.			
19				
20	*Corresponding author:			
21	Department of Veterinary Medicine			
22	University of Bari,			
23	Strada per Casamassima Km 3, 70010 Valenzano, Bari, Italy			
24	Tel: +390804679833			
25	Fax: +390804679843			
26	E-mail: nicola.decaro@ uniba.it			
27 28				

1 Abstract

Intra-vitam diagnosis of feline infectious peritonitis (FIP) is a challenge for veterinary diagnosticians, since there are no highly specific and sensitive assays currently available. With the aim to contribute to fill this diagnostic gap, a total of 61 effusions from cats with suspected effusive FIP were collected intra-vitam for detection of feline coronavirus (FCoV) antibodies and RNA by means of indirect immunofluorescence (IIF) assay and real-time RT-PCR (qRT-PCR), respectively. In 5 effusions there was no evidence for either FCoV RNA or antibodies, 51 and 52 specimens tested positive by IIF and qRT-PCR, respectively, although antibody titres \geq 1:1600, which are considered highly suggestive of FIP, were detected only in 37 effusions. Three samples with high antibody levels tested negative by qRT-PCR, whereas 18 qRT-PCR positive effusions contained no or low-titre antibodies. gRT-PCR positive samples with low antibody titres mostly contained low FCoV RNA loads, although the highest antibody titres were detected in effusions with C_T values >30. In conclusion, combining the two methods, i.e., antibody and RNA detection would help improving the intra-vitam diagnosis of effusive FIP. Key words: Feline infectious peritonitis; diagnosis; effusions; antibodies; viral RNA.

1. Introduction

2 Feline infectious peritonitis (FIP) is a lethal disease of cats caused by a hypervirulent 3 variant of feline coronavirus (FCoV), an alphacoronavirus that usually causes self-limiting 4 infections of the intestinal epithelium, leading to mild or no gastroenteric signs (Addie et al., 5 2009). Two different FCoV genotypes are currently known, FCoV type I (FCoV-I) and type II 6 (FCoV-II), both involved in the occurrence of mild gastroenteritis or fatal FIP (Decaro and 7 Buonavoglia, 2011). FIP is a perivascular pyogranulomatosis that may occur in two clinical 8 forms, effusive and non-effusive FIP, which are characterized by prevalence of effusions in the 9 body cavities and of pyogranulomatous lesion in organs, respectively. FIP diagnosis is challenging since the 'gold standard' is the post-mortem demonstration of FCoV antigens in 10 11 tissues by immunohistochemistry. Therefore, alternative tools are commonly used for the 12 intra-vitam diagnosis. Haematological and biochemical analyses can support a presumptive 13 diagnosis of FIP, but they usually require further investigations, such as assessment of the 14 FCoV antibody titers and molecular detection of FCoV RNA in the effusions (effusive form) or 15 bioptic samples (non-effusive FIP) from ill cats. Unfortunately, both methods lack specificity 16 and sensitivity, thus often leading to an inconclusive diagnosis (Addie et al., 2009). Recently, a 17 comparison between the intra-vitam detection of FCoV antibodies and that of FCoV RNA in 18 the effusions of cats with confirmed FIP has been carried out, showing a trend towards 19 negative or low antibody levels in cats with high viral RNA titers (Meli et al., 2013). However, 20 these findings have not been confirmed by other studies.

In the present paper, a total of 61 effusions from cats with confirmed FIP have been
 screened for FCoV antibodies and RNA, suggesting that intra-vitam diagnosis of effusive FIP
 needs to be assessed by means of combined antibody- and virus-detection methods.

24

25 **2. Materials and methods**

2.1. Sample collection

2	Effusions were collected intra-vitam from 61 cats whose FIP diagnosis was highly			
3	suspected since the clinical cases fulfilled all, or most, of the criteria for FIP diagnosis given in			
4	the European Advisory Board of Cat Disease recommendations (Addie et al., 2009,), as			
5	previously reported (Meli et al., 2013). All samples were sent to our lab for FIP confirmation			
6	by diagnostic labs that had carried out some preliminary analyses on the effusions, including			
7	Rivalta's test, total proteins, albumin/globulin ratio, total leukocyte counts and identity of			
8	cells (Table 1). Collected samples included 58 ascitic fluids and 3 pleuric effusions.			
9				
10	2.2. Detection of FCoV antibodies			
11	For FCoV antibody detection and titration, an indirect immunofluorescent (IIF) assay			
12	was used (Campolo et al., 2005), with minor modifications. Briefly, FCoV-II strain 25/92			
13	(Buonavoglia et al., 1995) was cultivated on Crandell feline kidney (CrFK) cells grown on			
14	coverslips. Infected cells were fixed in acetone 100% and twofold dilutions of the effusion			
15	(starting from dilution 1:100 to 1:51,200) were tested. Goat anti-cat IgG conjugated with			
16	fluorescein isothiocyanate was used as secondary antibody solution (Sigma Aldrich srl). The			
17	assay was proven to detect both FCoV-I and FCoV-II antibodies (Addie and Jarret, 1992;			
18	Campolo et al., 2005). Effusion with qRT-PCR positive and IIF-negative results were treated			
19	with ammonium thiocyanate to dissociate immune complexes, as previously described			
20	(Pullen et al., 1986; Macdonald et al., 1988).			
21				
22	2.3. Detection of FCoV RNA			
23	For FCoV RNA detection, 140 μl of the effusions were used for RNA extraction by			
24	means of QIAamp® Viral RNA Mini Kit (Qiagen S.p.A., Milan, Italy), following the			

25 manufacturer's protocol and the RNA templates were stored at –70°C until their use. FCoV

1 reverse-transcriptase quantitative PCR (FCoV qRT-PCR) was performed as previously 2 described (Gut et al., 1999), with minor modifications. In brief, a one-step method was 3 adopted using Platinum® Quantitative PCR SuperMix-UDG (Invitrogen srl, Milan, Italy) and 4 the following 50-µl mixture: 25 µl of master mix, 300 nM of primers FcoV1128f 5 (GATTTGATTTGGCAATGCTAGATTT) and FcoV1229r (AACAATCACTAGATCCAGACGTTAGCT), 6 200 nM of probe FCoV1200p (FAM- TCCATTGTTGGCTCGTCATAGCGGA-BHQ1) and 10 µl of 7 template RNA. The employed oligonucleotides bind to the 3' untranslated region (Gut et al., 8 1999). The thermal profile consisted of incubation with UDG at 50°C for 2 min and activation 9 of Platinum Taq DNA polymerase at 95° C for 2 min, followed by 45 cycles of denaturation at 10 95° C for 15 s, annealing at 48° C for 30 s and extension at 60° C for 30 s. Threshold cycle (C_T) 11 number was used as the measure of viral load. The lower the C_T, the more virus present in the 12 sample. 13 2.4 Statistical analysis 14 Spearman's rank correlation coefficient was calculated to evaluate the possible 15 correlation between viral RNA loads and antibody titres by the use of the online tool Social 16 Science Statistics (http://www.socscistatistics.com/tests/spearman). 17 3. Results 18 19 Fifty-one (48 ascitic and 3 pleuric fluids) of the 61 tested samples had FCoV antibody 20 (Table 2 and Fig. 1), although only 37 positive effusions contained antibody levels \geq 1:1,600, 21 which are considered highly suggestive of FIP diagnosis (Hartmann et al., 2003). Additional 22 13 samples presented FCoV antibody titres between 1:200 and 1:800, which are quite high for 23 an enteric infection but cannot be considered enough high for a systemic infection. Only one 24 effusion had an antibody titre of 1:100 and two samples displayed an antibody titre of 1:51,200. 25

1 By means of qRT-PCR, FCoV RNA was detected in a total of 52 samples (49 ascitic and 3 2 pleuric fluids). C_T values were generally above 30 (mean C_T value of 32.87), accounting for low 3 viral titres, with higher viral RNA loads (*C*^{*T*} values <30) being detected in only 11 effusions. 4 By comparing the results qRT-PCR with those of IIF assay using an antibody titre \geq 5 1:1,600 as cut-off (Fig. 1B), 6 samples tested negative by both assays (no viral RNA and no 6 FCoV antibodies), possibly accounting for diseases other than FIP, and 3 samples tested 7 negative only by qRT-PCR, although they contained FCoV antibody titres between 1:3,200 and 8 1:12,800, which were highly suggestive of FIP. Eighteen effusions were found to contain FCoV 9 RNA in the absence of specific antibodies (or at least in the presence of antibody titres less 10 than 1:1,600); 5 of these qRT-PCR positive specimens had no FCoV antibodies (or at least 11 antibody titres less than 1:100), while additional 13 effusions contained antibody titres 12 ranging from 1:100 to 1:800, which are not considered as suggestive of FIP. Therefore, based 13 only on antibody detection, a total of 18 cats whose effusions contained viral RNA were 14 predicted not to be affected by FIP, while taking advantage on molecular detection of FCoV 15 RNA, 3 animals with high antibody titres would have been considered FIP negative. 16 Unfortunately, samples with FCoV RNA tested negative by IIF even after treatment with the 17 chaotropic thiocyanate ion, which had been proven to dissociate immune complexes Pullen et 18 al., 1986).

19 Most effusions displaying the highest viral loads (C_T values <30) contained antibody 20 titres \ge 1:1,600; only one sample with a low C_T value displayed an antibody titre (1:200) not 21 suggestive of FIP (Table 2). Therefore, qRT-PCR positive samples with low antibody titres 22 mostly contained low FCoV RNA loads, although the highest antibody titres were detected in 23 effusions with C_T values >30.

Overall, no statistically significant correlation (R=0.1178; two-tailed *P-value*= 0.36576)
was found between viral RNA loads and antibody titres.

2

4. Discussion

3 Intra-vitam FIP diagnosis still represents a challenge for veterinarians and 4 diagnosticians, since there is no available tool to unambiguously diagnose the disease. FIP 5 cannot be differentiated from an FCoV enteric infection based on serology because the 6 antibodies are directed against the same pathogen and there are no relevant antigenic 7 differences between the enteric and hypervirulent strains. It is recognised that FIP-ill cats 8 have very high antibody titres in their serum and effusions due to the systemic spreading of 9 the virus through the infected monocytes/macrophages (Addie et al., 2009). However, 10 detection of high antibody titres alone is not a confirmatory test. In addition, the absence of 11 specific antibodies or the presence of very low antibody titres has been recently 12 demonstrated in the effusions of cats with confirmed FIP, likely due to antibody sequestration 13 by the high number of viral particles in the same sample of some cats (Meli et al. 2013). 14 Hartmann et al. (2003) demonstrated that about 10% of cats with FIP tested seronegative for 15 FCoV. However, in that study a transmissible gastroenteritis virus strain was used as antigen 16 for, which could affect the sensitivity of FCoV-antibody testing (Giori et al., 2011). 17 Accordingly, FCoV antibody titres were found to dramatically drop in terminal cases of FIP 18 (Pedersen, 1995). This phenomenon is not restricted to FIP, but it has been also demonstrated 19 for other viral infections characterised by high-level virus replication (Quirós-Roldán et al., 20 2000; Guihot et al., 2014). Overall, detection of FCoV antibodies in the effusions is affected by 21 poor specificity and sensitivity.

Molecular methods have been used for detection of FCoV RNA in the effusions of cats with suspected FIP (Gut et al., 1999; Hornyák e al., 2012; Soma et al., 2013; Doenges et al., 2017; Felten et al., 2017; Longstaff et al., 2017). However, these methods display similar issues related to the diagnostic performances (lack of sensitivity and specificity). In fact, they are not

able to distinguish between enteric and virulent FCoVs, since no specific genetic markers have
been identified for the latter strains. In addition, the enteric FCoVs have been proven to cause
transient viremia and even have a low replication in the blood (Can-Sahna et al., 2007; Kipar et
al., 2010; Fish et al., 2017), thus potentially being able to passively spread to the effusions
associated to other diseases.

6 A recent paper (Meli et al., 2013) has investigated the agreement between FCoV 7 antibody titres and RNA detection in the effusions of 13 cats with confirmed FIP, showing a 8 correlation between high amounts of virus and lower signals in IIF assay, likely due to the fact 9 that antibodies bound to viral antigens of the effusions are not able to bind to the antigens of 10 the FCoV-infected cells used in serological tests. Here, we have analysed by the same methods 11 the effusions of 61 cats with suspected FIP, thus including also potential samples from 12 animals with non-FIP related diseases. Accordingly, using an IIF antibody titre of 1:1,600 as a 13 cut-off, 5 samples tested negative by both IIF and qRT-PCR assays, possibly accounting for 14 diseases other than FIP, while 21 effusions gave contrasting results (low-titre or no antibodies 15 in the presence of FCoV RNA or viceversa). These 21 samples with conflicting results are 16 likely to be true positive since an IIF-negative result could be related to antibody 17 sequestration by high viral loads (Meli et al., 2013). In addition, Addie et al. (2014) 18 demonstrated that up to 43% antibody-positive effusions from FIP cases were negative for 19 FCoV RNA, likely as a consequence of PCR inhibition by interfering substances or RNA 20 degradation during sample transportation and storage. However, in the absence of 21 alternative diagnosis, even those 5 cats with neither FCoV antibodies nor RNA in their 22 effusions could not be definitively considered as non-FIP animals (Addie et al., 2014). 23 Unfortunately, clinical cases were mostly untraceable and confirmatory necropsy was not 24 done in any case, so that the lack of confirmatory testing represents the main limitation of the 25 present study.

In contrast with what observed by Meli et al. (2013), there was no statistically
 significant correlation between high viral loads and low-titre or negative antibody results. In
 fact, most effusions with low or no FCoV antibody titres displayed low amounts of virus,
 although samples with very high levels of FCoV RNA contained slightly lower antibody titres
 (generally <1:3,200) in comparison with effusions with the lowest amounts of virus, which
 reached IIF antibody titres of 1:26,600-1:51, 200 (Table 2).

7 The present study confirms that, when performed singularly, neither the detection of 8 FCoV nucleic acid nor that of specific antibodies in the effusions of cats with suspected FIP is 9 able to warrant an affordable diagnosis of the disease. Therefore, in order to increase the 10 diagnostic performances, we suggest combining the two methods (antibody and RNA detection) for an intra-vitam diagnosis of effusive FIP. Using this diagnostic approach, only 6 11 12 out of 61 cats whose effusions were analysed would be considered FIP negative, even if also in 13 these cases FIP could not be completely ruled out (Meli et al., 2013). Thus, the combined 14 serological and molecular protocol should improve the ability of laboratories to diagnose 15 effusive FIP, especially if the test results are supported by clinical and haematological 16 findings. However, intra-vitam diagnosis of non-effusive FIP still remains highly inconclusive, 17 even if recent studies tried to address this issue (Doenges et al., 2016). Therefore, future 18 studies are needed to develop and validate tools for the intra-vitam diagnosis of non-effusive 19 FIP, which still represents a challenge for veterinary diagnosticians.

20

21 Conflict of interest statement

22 There is no conflict of interest of any authors in relation to the submission.

23

24 Acknowledgments

- 1 This research did not receive any specific grant from funding agencies in the public,
- 2 commercial, or not-for-profit sectors.
- 3

4 **References**

- 5
 - Addie, D.D., Jarrett, O., 1992. Feline coronavirus antibodies in cats. Vet. Rec., 131, 202–203.
- 6 7
- Addie, D.D., Belák, S., Boucraut-Baralon, C., Egberink, H., Frymus, T., Gruffydd-Jones, T.,
- 9 Hartmann, K., Hosie, M.J., Lloret, A., Lutz, H., Marsilio, F., Pennisi, M.G., Radford, A.D., Thiry,
 10 E., Truyen, U., Horzinek, M.C., 2009. Feline infectious peritonitis. ABCD guidelines on
- 11 prevention and management. J. Feline Med. Surg. 11, 594-604.
- 12
- Buonavoglia C., Sagazio P., Cirone F., Tempesta M., Marsilio F., 1995. Isolamento e
 caratterizzazione di uno stipite di virus della peritonite infettiva felina. Veterinaria, 9, 91-94.
- 15
- Campolo, M., Desario, C., Ricci, D., Elia, G., Decaro, N., Martella, V., Tempesta, M., Di Trani, L.,
 Cavaliere, N., Buonavoglia, C., 2005 Identification of a feline coronavirus type I strain from a
 cat with feline infectious peritonitis by RT-PCR and phylogenetic analysis. New Microbiol. 28,
 127-133.
- 20
 21 Can-Sahna, K., Soydal Ataseven, V., Pinar, D., Oğuzoğlu, T.C., 2007. The detection of feline
 22 coronaviruses in blood samples from cats by mRNA RT-PCR. J. Feline Med. Surg. 9, 369-372.
 23
- Decaro, N., Buonavoglia, C., 2011. Canine coronavirus: not only an enteric pathogen. Vet. Clin.
 North Am. Small Anim. Pract. 41, 1121-1132.
- 26
 27 Doenges, S.J., Weber, K., Dorsch, R., Fux, R., Fischer, A., Matiasek, L.A., Matiasek, K., Hartmann,
 28 K., 2016. Detection of feline coronavirus in cerebrospinal fluid for diagnosis of feline
 29 infectious peritonitis in cats with and without neurological signs. J. Feline Med. Surg. 18, 10430 109.
- 31
- 32 Doenges, S.J., Weber, K., Dorsch, R., Fux, R., Hartmann, K., 2017. Comparison of real-time 33 reverse transcriptase polymerase chain reaction of peripheral blood mononuclear cells,
- serum and cell-free body cavity effusion for the diagnosis of feline infectious peritonitis. J.
 Felice Med Society 10, 244, 250
- 35 Feline Med. Surg. 19, 344-350.
- 36
- Felten, S., Weider, K., Doenges, S., Gruendl, S., Matiasek, K., Hermanns, W., Mueller, E., Matiasek, L.,
- Fischer, A., Weber, K., Hirschberger, J., Wess, G., Hartmann, K., 2017. Detection of feline
 coronavirus spike gene mutations as a tool to diagnose feline infectious peritonitis. J. Feline Med.
 Surg. 19, 321-335.
- 41
- 42 Fish, E.J., Diniz, P.P.V., Juan, Y.C., Bossong, F., Collisson, E.W., Drechsler, Y., Kaltenboeck , B., 2017. A
- 43 cross-sectional quantitative RT-PCR study of feline coronavirus viremia and replication in
- 44 peripheral blood of healthy shelter cats in Southern California. J. Feline Med. Surg.. doi:
- 45 10.1177/1098612X17705227.
- 46

- 1 Giori, L., Giordano, A., Giudice, C., Grieco, V., Paltrinieri, S., 2011. Performances of different 2 diagnostic tests for feline infectious peritonitis in challenging clinical cases. J. Small Anim. 3 Pract. 52, 152-157. 4 5 Guihot, A., Luyt, C.E., Parrot, A., Rousset, D., Cavaillon, J.M., Boutolleau, D., Fitting, C., Pajanirassa, P., Mallet, A., Fartoukh, M., Agut, H., Musset, L., Zoorob, R., Kirilovksv, A., 6 7 Combadière, B., van der Werf, S., Autran, B., Carcelain, G; FluBAL Study Group, 2014. Low 8 titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza 9 A(H1N1) 2009 infection. Am. J. Respir. Crit. Care Med. 189, 1240-1249. 10 11 Gut, M., Leutenegger, C.M., Huder, JB., Pedersen, N.C., Lutz, H., 1999. One-tube fluorogenic reverse transcription-polymerase chain reaction for the quantitation of feline coronaviruses. 12 13 I. Virol. Methods 77, 37-46. 14 15 Hartmann, K., Binder, C., Hirschberger, J., Cole, D., Reinacher, M., Schroo, S., Frost, J., Egberink, H., 16 Lutz, H., Hermanns, W., 2003. Comparison of different tests to diagnose feline infectious 17 peritonitis. J. Vet. Intern. Med. 17, 781-90. 18 19 Hornyák, A., Bálint, A., Farsang, A., Balka, G., Hakhverdyan, M., Rasmussen, T.B., Blomberg, J., Belák, 20 S., 2012. Detection of subgenomic mRNA of feline coronavirus by real-time polymerase chain 21 reaction based on primer-probe energy transfer (P-sg-QPCR). J. Virol. Methods 181, 155-163. 22 23 Kipar, A., Meli, M.L., Baptiste, K.E., Bowker, L.J., Lutz, H., 2010. Sites of feline coronavirus 24 persistence in healthy cats. J. Gen. Virol. 91, 1698-1707. 25 26 Longstaff, L., Porter, E., Crossley, V.J., Hayhow, S.E., Helps, C.R., Tasker, S., 2017. Feline coronavirus 27 quantitative reverse transcriptase polymerase chain reaction on effusion samples in cats with and 28 without feline infectious peritonitis. J. Feline Med. Surg. 19, 240-245. 29 30 Meli, M.L., Burr, P., Decaro, N., Graham, E., Jarrett, O., Lutz, H., McDonald, M., Addie, D.D., 2013. 31 Samples with high virus load cause a trend toward lower signal in feline coronavirus antibody 32 tests. J. Feline Med. Surg. 15, 295-299. 33 34 Macdonald, R.A., Hosking, C.S., Jones, C.L., 1988. The measurement of relative antibody affinity by 35 ELISA using thiocyanate elution. J. Immunol. Methods 106, 191-194. 36 37 Pedersen, N.C. (1995). The history and interpretation of feline coronavirus serology. Feline 38 Pract. 23, 46–51. 39 40 Pullen, G.R., Fitzgerald, M.G., Hosking, C.S., 1986. Antibody avidity determination by ELISA using 41 thiocyanate elution. J. Immunol. Methods 86, 83-87. 42 43 Quirós-Roldán, E., Piédrola, G., Maroto, M.C., 2000. Anti-hepatitic C virus antibodies hidden in 44 circulating antibody/antigen aggregates in HCV-RNA positive patients. Microbios. 103, 59-64. 45 46 Simons, F.A., Vennema, H., Rofina, J.E., Pol, J.M., Horzinek, M.C., Rottier, P.J., Egberink, H.F., 2004. A 47 mRNA PCR for the diagnosis of feline infectious peritonitis. J. Virol. Methods 124, 111-116. 48 49 Soma, T., Wada, M., Taharaguchi, S., Tajima, T., 2013. Detection of ascitic feline coronavirus RNA 50 from cats with clinically suspected feline infectious peritonitis. J. Vet. Med. Sci. 75, 1389-1392. 51
 - 11

Figure legend.

- Fig. 1. Comparison between indirect immunofluorescence (IIF) assay and real-time RT-PCR
 (qRT-PCR) carried out on 61 effusions from cats with suspected feline infectious peritonitis
 (FIP). Numbers indicate the samples positive (+) or negative (-) for FCoV antibodies or RNA.
 Results according to both techniques are shown in bold. For IIF assay, the cut-off was set to
 1:100 (A) or 1:1600 (B), the latter being considered highly suggestive of FIP.
 Table 1. Effusion features used as criteria for FIP diagnosis.
 - FeatureValueRivalta's testPositiveTotal proteins>35 g/lAlbumin/globulin<0.8</td>Total leukocytes<2 × 10⁹/lIdentity of cellsNeutrophils+macrophages

Table 2. FCoV antibody titres and RNA loads in the effusions of 61 cats with suspected

FIP.

- . .

Cat no.	Sample type	FCoV RNA loads ^a	FCoV antibody titres ^b
1	Ascitic fluid	40.38	25,600
2	Ascitic fluid	>45	800
3	Ascitic fluid	>45	<100
4	Ascitic fluid	32.31	1600
5	Ascitic fluid	>45	<100
6	Ascitic fluid	>45	<100
7	Ascitic fluid	36.21	12,800
8	Ascitic fluid	34.82	1,600
9	Ascitic fluid	37.96	6,400
10	Ascitic fluid	35.79	1600
11	Ascitic fluid	35.14	1600
12	Ascitic fluid	>45	<100
13	Ascitic fluid	37.24	<100
14	Ascitic fluid	>45	<100

15 Ascitic fluid >445 6,400 17 Ascitic fluid >445 12,800 18 Ascitic fluid 33.25 800 19 Ascitic fluid 30.63 400 21 Ascitic fluid 36.97 25,600 22 Ascitic fluid 26.34 1,600 24 Ascitic fluid 36.20 6,400 25 Ascitic fluid 31.18 800 26 Ascitic fluid 32.26 800 28 Ascitic fluid 32.26 800 28 Ascitic fluid 32.20 400 30 Ascitic fluid 21.02 400 30 Ascitic fluid 24.80 3,200 31 Ascitic fluid 24.97 12,800 32 Ascitic fluid 24.03 3,200 31 Ascitic fluid 35.9 3,200 32 Ascitic fluid 35.9 3,200 34 Ascitic fluid 35.9 3,200 35 Ascitic fluid 35.9 3,200				
17Ascitic fluid> 45 $12,800$ 18Ascitic fluid 33.25 800 19Ascitic fluid 37.46 <100	15	Ascitic fluid	34.04	12,800
18 Ascitic fluid 33.25 800 19 Ascitic fluid 30.63 400 20 Ascitic fluid 30.63 400 21 Ascitic fluid 36.97 25,600 22 Ascitic fluid 26.34 1,600 24 Ascitic fluid 36.20 6,400 25 Ascitic fluid 31.18 800 26 Ascitic fluid 32.266 800 28 Ascitic fluid 31.02 400 30 Ascitic fluid 21.11 3,200 31 Ascitic fluid 24.80 3,200 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 37.04 12,800 35 Ascitic fluid 37.99 3,200 36 Ascitic fluid 32,87 800 38 Ascitic fluid 24,87 800 39 Ascitic fluid 32,87 <td>16</td> <td>Ascitic fluid</td> <td>>45</td> <td>6,400</td>	16	Ascitic fluid	>45	6,400
19 Ascitic fluid 37.46 <100	17	Ascitic fluid	>45	12,800
20 Ascitic fluid 30.63 400 21 Ascitic fluid 36.97 25,600 22 Ascitic fluid 26.34 1,600 24 Ascitic fluid 36.20 6,400 25 Ascitic fluid 36.20 6,400 26 Ascitic fluid 31.8 800 27 Ascitic fluid 32.66 800 28 Ascitic fluid 31.02 400 30 Ascitic fluid 24.80 3,200 31 Ascitic fluid 21.11 3,200 32 Ascitic fluid 27.3 1,2800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 37.04 12,800 35 Ascitic fluid 35.99 3,200 36 Ascitic fluid 32.87 800 38 Ascitic fluid 30.27 51,200 36 Ascitic fluid 26.94 1,600 42 Ascitic fluid 30.27 51,200 43 Pleuric effusion 29.09 200	18	Ascitic fluid	33.25	800
21 Ascitic fluid 36.97 25,600 22 Ascitic fluid 26.34 1,600 24 Ascitic fluid 36.20 6,400 25 Ascitic fluid 30.20 6,400 26 Ascitic fluid 31.18 800 27 Ascitic fluid 32.66 800 28 Ascitic fluid 31.02 400 30 Ascitic fluid 21.11 3,200 31 Ascitic fluid 21.11 3,200 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 35.99 3,200 35 Ascitic fluid 32,87 800 38 Ascitic fluid 32,87 800 38 Ascitic fluid 30.27 51,200 34 Ascitic fluid 26.94 1,600 42 Ascitic fluid 26.94 1,600 42 Ascitic fluid 34.10 400 46 Ascitic fluid 34.10 400	19	Ascitic fluid	37.46	<100
22 Ascitic fluid >45 3,200 23 Ascitic fluid 26.34 1,600 24 Ascitic fluid 36.20 6,400 25 Ascitic fluid 31.18 800 26 Ascitic fluid 32.66 800 28 Ascitic fluid 31.02 400 30 Ascitic fluid 21.11 3,200 31 Ascitic fluid 29.73 12,800 32 Ascitic fluid 29.73 12,800 31 Ascitic fluid 37.04 12,800 32 Ascitic fluid 37.04 12,800 34 Ascitic fluid 35.99 3,200 35 Ascitic fluid 32.87 800 36 Ascitic fluid 32,87 800 38 Ascitic fluid 25.95 3,200 37 Ascitic fluid 25.95 3,200 41 Ascitic fluid 25.95 3,200 42 Ascitic fluid 25.95 3,200 44 Ascitic fluid 30.27 51,200	20	Ascitic fluid	30.63	400
22 Ascitic fluid >45 3,200 23 Ascitic fluid 26.34 1,600 24 Ascitic fluid 36.20 6,400 25 Ascitic fluid 33.18 800 26 Ascitic fluid 32.66 800 28 Ascitic fluid 31.02 400 30 Ascitic fluid 21.11 3,200 31 Ascitic fluid 21.11 3,200 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 37.04 12,800 35 Ascitic fluid 35.99 3,200 37 Ascitic fluid 32,87 800 38 Ascitic fluid 22,87 800 39 Ascitic fluid 22,99 3,200 37 Ascitic fluid 26,94 1,600 41 Ascitic fluid 26,94 1,600 42 Ascitic fluid 34.10 400 43 Pleuric effusion 29.09 200	21	Ascitic fluid	36.97	25,600
23 Ascitic fluid 26.34 1,600 24 Ascitic fluid 36.20 6,400 25 Ascitic fluid 33.18 800 26 Ascitic fluid 32.66 800 28 Ascitic fluid 31.02 400 30 Ascitic fluid 21.11 3,200 31 Ascitic fluid 29.73 12,800 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 34.60 51,200 35 Ascitic fluid 35.99 3,200 36 Ascitic fluid 32,87 800 38 Ascitic fluid 28,47 800 39 Ascitic fluid 26.94 1,600 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 27.69 1,600 43 Pleuric effusion 29.09 200 44 Ascitic fluid 34.35 800 45 Ascitic fluid 34.35 800 <td>22</td> <td>Ascitic fluid</td> <td>>45</td> <td></td>	22	Ascitic fluid	>45	
24 Ascitic fluid 36.20 6,400 25 Ascitic fluid 33.18 800 26 Ascitic fluid 32.66 800 28 Ascitic fluid 35.2 12,800 29 Ascitic fluid 21.02 400 30 Ascitic fluid 24.80 3,200 31 Ascitic fluid 29.73 12,800 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 35.99 3,200 35 Ascitic fluid 35.99 3,200 36 Ascitic fluid 32,87 800 38 Ascitic fluid 28,97 800 39 Ascitic fluid 26,94 1,600 42 Ascitic fluid 26,94 1,600 43 Pleuric effusion 29.09 200 44 Ascitic fluid 34.10 400 45 Ascitic fluid 34.10 400 46 Ascitic fluid 34.10 400	23	Ascitic fluid	26.34	
25 Ascitic fluid 40.42 1,600 26 Ascitic fluid 33.18 800 27 Ascitic fluid 35.2 12,800 29 Ascitic fluid 21.02 400 30 Ascitic fluid 21.02 400 31 Ascitic fluid 21.11 3,200 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 34.60 51,200 35 Ascitic fluid 35.99 3,200 36 Ascitic fluid 38.48 800 38 Ascitic fluid 28,87 800 39 Ascitic fluid 26,94 1,600 41 Ascitic fluid 26,94 1,600 42 Ascitic fluid 27,69 1,600 45 Ascitic fluid 28,48 6,400 47 Ascitic fluid 38,57 100 48 Ascitic fluid 38,57 410 48 Ascitic fluid 38,57 100	24	Ascitic fluid	36.20	
26 Ascitic fluid 33.18 800 27 Ascitic fluid 32.66 800 28 Ascitic fluid 31.02 400 30 Ascitic fluid 24.80 3,200 31 Ascitic fluid 21.11 3,200 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 37.04 12,800 36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 38.48 800 38 Ascitic fluid 32,87 800 39 Ascitic fluid 26,94 1,600 41 Ascitic fluid 26,94 1,600 42 Ascitic fluid 27.69 1,600 44 Ascitic fluid 28.48 6,400 47 Ascitic fluid 38.57 <100				
27 Ascitic fluid 32.66 800 28 Ascitic fluid 31.02 400 30 Ascitic fluid 24.80 3,200 31 Ascitic fluid 21.11 3,200 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 34.60 51,200 35 Ascitic fluid 35.99 3,200 36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 32,87 800 38 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 26.94 1,600 42 Ascitic fluid 27.69 1,600 43 Pleuric effusion 29.09 200 44 Ascitic fluid 28.48 6,400 47 Ascitic fluid 34.10 400 46 Ascitic fluid 38.57 <100				
28 Ascitic fluid 35.2 12,800 29 Ascitic fluid 31.02 400 30 Ascitic fluid 24.80 3,200 31 Ascitic fluid 21.11 3,200 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 37.04 12,800 36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 38.48 800 38 Ascitic fluid 22,87 800 39 Ascitic fluid 24,87 800 39 Ascitic fluid 26,94 1,600 41 Ascitic fluid 26,94 1,600 42 Ascitic fluid 30.27 51,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 27.69 1,600 45 Ascitic fluid 34.10 400 46 Ascitic fluid 38.57 <100				
29 Ascitic fluid 31.02 400 30 Ascitic fluid 24.80 3,200 31 Ascitic fluid 21.11 3,200 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 34.60 51,200 35 Ascitic fluid 37.04 12,800 36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 32,87 800 38 Ascitic fluid 24.18 6,400 40 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 20.27 51,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 27.69 1,600 45 Ascitic fluid 28.48 6,400 47 Ascitic fluid 38.57 <100				
30 Ascitic fluid 24.80 3,200 31 Ascitic fluid 29.73 12,800 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 34.60 51,200 35 Ascitic fluid 35.99 3,200 36 Ascitic fluid 32,87 800 38 Ascitic fluid 22,87 800 39 Ascitic fluid 26.94 1,600 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 27.69 1,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 27.69 1,600 45 Ascitic fluid 34.35 800 46 Ascitic fluid 38.57 <100				
31 Ascitic fluid 21.11 3,200 32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 34.60 51,200 35 Ascitic fluid 37.04 12,800 36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 32,87 800 38 Ascitic fluid 26.94 1,600 40 Ascitic fluid 26.94 1,600 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 27.69 1,600 43 Pleuric effusion 29.09 200 44 Ascitic fluid 27.69 1,600 45 Ascitic fluid 34.35 800 46 Ascitic fluid 38.57 <100				
32 Ascitic fluid 29.73 12,800 33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 37.04 12,800 36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 38.48 800 38 Ascitic fluid 32,87 800 39 Ascitic fluid 24.18 6,400 40 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 27.69 1,600 43 Pleuric effusion 29.09 200 44 Ascitic fluid 27.69 1,600 45 Ascitic fluid 28.48 6,400 46 Ascitic fluid 38.57 <100				
33 Pleuric effusion 33.34 12,800 34 Ascitic fluid 34.60 51,200 35 Ascitic fluid 37.04 12,800 36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 32,87 800 38 Ascitic fluid 24.18 6,400 40 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 30.27 51,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 34.10 400 45 Ascitic fluid 34.10 400 46 Ascitic fluid 34.35 800 47 Ascitic fluid 34.35 800 48 Ascitic fluid 38.57 <100				
34 Ascitic fluid 34.60 51,200 35 Ascitic fluid 37.04 12,800 36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 38.48 800 38 Ascitic fluid 32,87 800 39 Ascitic fluid 24.18 6,400 40 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 30.27 51,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 34.10 400 45 Ascitic fluid 34.10 400 46 Ascitic fluid 34.35 800 47 Ascitic fluid 34.35 800 48 Ascitic fluid 38.57 <100				
35 Ascitic fluid 37.04 12,800 36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 38.48 800 38 Ascitic fluid 32,87 800 39 Ascitic fluid 24.18 6,400 40 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 30.27 51,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 27.69 1,600 45 Ascitic fluid 28.48 6,400 47 Ascitic fluid 28.48 6,400 47 Ascitic fluid 38.57 <100				
36 Ascitic fluid 35.99 3,200 37 Ascitic fluid 38.48 800 38 Ascitic fluid 32,87 800 39 Ascitic fluid 24.18 6,400 40 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 30.27 51,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 27.69 1,600 45 Ascitic fluid 28.48 6,400 46 Ascitic fluid 34.35 800 47 Ascitic fluid 38.57 <100				
37 Ascitic fluid 38.48 800 38 Ascitic fluid 32,87 800 39 Ascitic fluid 24.18 6,400 40 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 30.27 51,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 34.10 400 45 Ascitic fluid 34.10 400 46 Ascitic fluid 34.35 800 47 Ascitic fluid 34.35 800 48 Ascitic fluid 38.57 <100				
38 Ascitic fluid 32,87 800 39 Ascitic fluid 24.18 6,400 40 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 30.27 51,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 34.10 400 45 Ascitic fluid 34.10 400 46 Ascitic fluid 28.48 6,400 47 Ascitic fluid 34.35 800 48 Ascitic fluid 38.57 <100				
39 Ascitic fluid 24.18 6,400 40 Ascitic fluid 25.95 3,200 41 Ascitic fluid 26.94 1,600 42 Ascitic fluid 30.27 51,200 43 Pleuric effusion 29.09 200 44 Ascitic fluid 27.69 1,600 45 Ascitic fluid 34.10 400 46 Ascitic fluid 28.48 6,400 47 Ascitic fluid 34.35 800 48 Ascitic fluid 38.57 <100				
40Ascitic fluid25.953,20041Ascitic fluid26.941,60042Ascitic fluid30.2751,20043Pleuric effusion29.0920044Ascitic fluid27.691,60045Ascitic fluid34.1040046Ascitic fluid28.486,40047Ascitic fluid34.3580048Ascitic fluid38.57<100				
41Ascitic fluid26.941,60042Ascitic fluid30.2751,20043Pleuric effusion29.0920044Ascitic fluid27.691,60045Ascitic fluid34.1040046Ascitic fluid28.486,40047Ascitic fluid34.3580048Ascitic fluid38.57<100				
42Ascitic fluid30.2751,20043Pleuric effusion29.0920044Ascitic fluid27.691,60045Ascitic fluid34.1040046Ascitic fluid28.486,40047Ascitic fluid34.3580048Ascitic fluid30.57<100				
43Pleuric effusion29.0920044Ascitic fluid27.691,60045Ascitic fluid34.1040046Ascitic fluid28.486,40047Ascitic fluid34.3580048Ascitic fluid40.56<100				
44Ascitic fluid27.691,60045Ascitic fluid34.1040046Ascitic fluid28.486,40047Ascitic fluid34.3580048Ascitic fluid40.56<100				
45Ascitic fluid34.1040046Ascitic fluid28.486,40047Ascitic fluid34.3580048Ascitic fluid40.56<100				
46Ascitic fluid28.486,40047Ascitic fluid34.3580048Ascitic fluid40.56<100				,
47Ascitic fluid34.3580048Ascitic fluid40.56<100				
48Ascitic fluid40.56<10049Ascitic fluid38.57<100				
49Ascitic fluid38.57<10050Ascitic fluid32.0540051Ascitic fluid35.171,60052Ascitic fluid29.0412,80053Ascitic fluid37.566,40054Pleuric effusion35.9720055Ascitic fluid39.2325,60056Ascitic fluid32.326,40058Ascitic fluid36.256,40059Ascitic fluid37.8012,80060Ascitic fluid41.141,600				
50Ascitic fluid32.0540051Ascitic fluid35.171,60052Ascitic fluid29.0412,80053Ascitic fluid37.566,40054Pleuric effusion35.9720055Ascitic fluid35.35<100				
51Ascitic fluid35.171,60052Ascitic fluid29.0412,80053Ascitic fluid37.566,40054Pleuric effusion35.9720055Ascitic fluid35.35<100				
52 Ascitic fluid 29.04 12,800 53 Ascitic fluid 37.56 6,400 54 Pleuric effusion 35.97 200 55 Ascitic fluid 35.35 <100				
53 Ascitic fluid 37.56 6,400 54 Pleuric effusion 35.97 200 55 Ascitic fluid 35.35 <100				
54Pleuric effusion35.9720055Ascitic fluid35.35<100				
55Ascitic fluid35.35<10056Ascitic fluid39.2325,60057Ascitic fluid32.326,40058Ascitic fluid36.256,40059Ascitic fluid37.8012,80060Ascitic fluid41.141,600				
56Ascitic fluid39.2325,60057Ascitic fluid32.326,40058Ascitic fluid36.256,40059Ascitic fluid37.8012,80060Ascitic fluid41.141,600				
57Ascitic fluid32.326,40058Ascitic fluid36.256,40059Ascitic fluid37.8012,80060Ascitic fluid41.141,600				
58 Ascitic fluid 36.25 6,400 59 Ascitic fluid 37.80 12,800 60 Ascitic fluid 41.14 1,600				
59Ascitic fluid37.8012,80060Ascitic fluid41.141,600				
60 Ascitic fluid 41.14 1,600			36.25	
			37.80	
61 Ascitic fluid 32.57 100	60	Ascitic fluid	41.14	1,600
	61	Ascitic fluid	32.57	100

- ^a FCoV RNA loads are expressed as C_T values. Values >45 are considered negative results.
- 2 ^b FCoV antibody titres are expressed as the reciprocal of the highest sample dilution able to
- 3 generate fluorescence in FCoV-infected cells.
- 4
- 5